{ "event": { "ticker": "PRAX", "company": "Praxis Precision Medicines, Inc.", "drug": "relutrigine", "application_type": "NDA", "indication": "SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)", "pdufa_date": "2026-12-27" }, "display": { "company": "Praxis", "drug": "relutrigine", "indication_en": "SCN2A/SCN8A epileptic encephalopathies", "indication_zh": "SCN2A/SCN8A 癫痫性脑病" }, "probability_approval": 0.8, "confidence": "medium", "base_rate_used": 0.76, "key_factors": [ { "factor": "The registrational cohort met its primary endpoint by a wide margin", "direction": "+", "step": "medium", "evidence": "In the registrational cohort (cohort 2) of the EMBOLD study, relutrigine reduced monthly motor seizures by 53% relative to placebo over 16 weeks (p<0.0002). The interim analysis that stopped the study was to be tested at a 4% significance level, so the result cleared its threshold with room to spare. Key secondary endpoints were also significant: motor seizure-free days rose 66.2% (p=0.0340), and the clinician and caregiver global impression scores favoured relutrigine (-2.62, p<0.0001; -3.7, p=0.002). The first cohort, run under the same design at a lower starting dose, showed a 46% placebo-adjusted reduction (p=0.0354; 15 patients on relutrigine, 7 placebo periods). More than 80% of patients were already taking sodium channel blockers at baseline. Praxis says the effect was consistent in SCN2A and SCN8A patients; subgroup figures are not public.", "source": "EMBOLD poster, American Epilepsy Society meeting, December 2025 (Kamireddy et al.): https://praxismedicines.com/wp-content/uploads/2025/12/Gil-Nagel_AES2025_EMBOLD-Topline.pdf; Praxis 8-K, 2025-12-08: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000114/prax-20251204.htm; Praxis press release, 2025-11-04: https://www.globenewswire.com/news-release/2025/11/04/3180282/0/en/praxis-announces-accelerated-development-path-for-relutrigine-in-scn2a-and-scn8a-dee-patients-following-positive-fda-feedback.html; Praxis corporate presentation, August 2026: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxiscorporatedeckaugus.htm" }, { "factor": "FDA agreed in advance that this one study could support the application", "direction": "+", "step": "small", "evidence": "Praxis reported on 4 November 2025 that, after a Type B meeting and written advice on the protocol and statistical analysis plan, it had reached alignment with FDA that the ongoing EMBOLD study could serve as the basis of substantial evidence of effectiveness, and that FDA agreed a positive interim analysis could serve as the basis of the NDA. FDA had granted Breakthrough Therapy Designation in July 2025 on the first cohort and its 11-month open-label follow-up. After the interim result, a further discussion with FDA in December 2025 led the company to confirm it would file. These are the company's accounts; FDA's meeting minutes are not public.", "source": "Praxis press release, 2025-11-04: https://www.globenewswire.com/news-release/2025/11/04/3180282/0/en/praxis-announces-accelerated-development-path-for-relutrigine-in-scn2a-and-scn8a-dee-patients-following-positive-fda-feedback.html; Praxis 8-K exhibit 99.1, 2025-11-05: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm; Praxis 8-K, 2025-07-17: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000086/prax-20250717.htm; Praxis 8-K, 2025-12-11: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/prax-20251209.htm" }, { "factor": "Review signals reported so far are favourable", "direction": "+", "step": "small", "evidence": "FDA accepted the application for priority review (announced 30 March 2026). On 6 August 2026 Praxis said the mid-cycle meeting was complete, that FDA had identified no major safety or efficacy concerns to date, and that the agency confirmed no advisory committee meeting is planned; FDA's advisory committee calendar shows no meeting on the drug. An FDA inspection of the sponsor under the Bioresearch Monitoring programme, covering data integrity and the statistical and interim analyses, ended with no Form 483. Two limits: these are the sponsor's summaries, and the mid-cycle statement says nothing about manufacturing.", "source": "Praxis press release, 2026-03-30: https://www.globenewswire.com/news-release/2026/03/30/3264996/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Relutrigine-in-Patients-with-SCN2A-and-SCN8A-DEEs.html; Praxis 8-K, 2026-04-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/prax-20260406.htm; Praxis 8-K exhibit 99.1, 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm; Praxis 10-Q filed 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm; FDA advisory committee calendar, viewed 2026-10-05: https://www.fda.gov/advisory-committees/advisory-committee-calendar" }, { "factor": "A small study with an unusual control", "direction": "-", "step": "small", "evidence": "Only 53 children were randomized in the registrational cohort, against a planned 80, because the study stopped at the interim analysis. There was no parallel placebo group. Every patient was assigned to relutrigine; 25 were also assigned one blinded 4-week placebo period within the 16 weeks. The placebo-adjusted result therefore compares time on relutrigine in 51 patients with a single 4-week placebo period in 25 patients, most of whom also count among the 51. The agreed primary analysis was an ANCOVA on log-transformed seizure counts with treatment as the only stated factor. Not public: where in the 16 weeks the placebo period fell, and how carry-over from earlier dosing, or a rebound after stopping the drug, was handled. PubMed lists no peer-reviewed report of the results; the public record is a conference poster and company releases.", "source": "EMBOLD poster, December 2025: https://praxismedicines.com/wp-content/uploads/2025/12/Gil-Nagel_AES2025_EMBOLD-Topline.pdf; Praxis press release, 2025-11-04: https://www.globenewswire.com/news-release/2025/11/04/3180282/0/en/praxis-announces-accelerated-development-path-for-relutrigine-in-scn2a-and-scn8a-dee-patients-following-positive-fda-feedback.html; ClinicalTrials.gov NCT05818553: https://clinicaltrials.gov/study/NCT05818553; PubMed search for relutrigine / PRAX-562 on 2026-10-05, including the review at https://doi.org/10.3390/cimb48080830" }, { "factor": "FDA took three extra months to review added analyses of the efficacy data", "direction": "-", "step": "small", "evidence": "On 29 June 2026 FDA moved the goal date from 27 September to 27 December 2026 after Praxis submitted additional sensitivity analyses of existing clinical data, which FDA deemed a major amendment. Praxis said no new studies were requested and no safety or manufacturing concerns were cited. According to TD Cowen, as reported by Fierce Biotech, the company described the submission as simple and limited to minor sensitivity analyses and changes to how data were formatted and presented; what the analyses tested is not public. An extension is not usually bad news. FDA's user-fee commitments list a major re-analysis of submitted studies as a typical major amendment and say an extension should, \"except in rare circumstances\", be used when the new information could lead to approval in the current cycle. Jefferies, cited by BioSpace, counts more than 80% of extended reviews ending in approval, and Rhythm's setmelanotide supplement was approved in March 2026 after an extension for the same stated reason. Still, it shows FDA wanted more than the original package on the one study the application rests on. Only one extension is allowed per cycle; 27 December 2026 is a Sunday.", "source": "Praxis 8-K, 2026-06-29: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm; Fierce Biotech, 2026-06-30: https://www.fiercebiotech.com/biotech/praxis-faces-fda-delay-analysts-point-finger-agency-layoffs; BioSpace, 2026-06-30: https://www.biospace.com/fda/fda-hits-praxis-with-3-month-delay-for-epilepsy-drug-verdict; PDUFA performance goals FY2023-2027, section I.A.5: https://www.fda.gov/media/151712/download; Rhythm Pharmaceuticals press release, 2026-03-19: https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm" }, { "factor": "Few patients have been exposed", "direction": "-", "step": "small", "evidence": "The blinded safety data cover 67 children: 16 in the first cohort and 51 in the registrational cohort, each for up to 16 weeks. Long-term results reported so far cover 13 patients followed for 11 months. Two phase 1 studies in healthy adults enrolled 112 and 48 participants. EMERALD, a larger placebo-controlled study in about 200 patients with epileptic encephalopathies of any cause, is still blinded, and how much of its safety data FDA has received is not public. In the registrational cohort one death and one withdrawal of consent are listed as discontinuations on placebo. The poster's counts (53 randomized, 51 in the relutrigine safety analysis) suggest both patients left before receiving relutrigine; the cause of death is not public, and Praxis says no serious adverse event was drug-related. This is a thin base for a new chemical entity meant for long-term use in children, though Praxis reports that FDA raised no major safety concern at mid-cycle.", "source": "EMBOLD poster, December 2025: https://praxismedicines.com/wp-content/uploads/2025/12/Gil-Nagel_AES2025_EMBOLD-Topline.pdf; American Epilepsy Society abstract 1.38, December 2025: https://aesnet.org/abstractslisting/relutrigine-demonstrates-sustained-seizure-reduction-with-continued-exposure-on-top-of-standard-of-care-results-from-the-embold-open-label-extension; phase 1 posters: https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf and https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-102_Final_QRcode.pdf; Praxis 8-K exhibit 99.1, 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm; ClinicalTrials.gov NCT07010471: https://clinicaltrials.gov/study/NCT07010471" }, { "factor": "Reported tolerability is clean", "direction": "+", "step": "small", "evidence": "In the registrational cohort the commonest adverse events occurred at similar or lower exposure-adjusted rates on relutrigine than on placebo (per 100 patient-months: pyrexia 11.74 vs 13.35; somnolence 9.13 vs 13.35; diarrhoea 4.57 vs 8.90), with upper respiratory infection higher on relutrigine (9.79 vs 4.45). Praxis reports no drug-related serious adverse events, no dose reductions, and no clinically significant findings in vital signs, laboratory tests or ECGs; one patient stopped for an adverse event during a relutrigine period. The ongoing EMERALD study excludes patients with familial short QT syndrome, Brugada syndrome and certain arrhythmias, which shows cardiac conduction is a monitored risk; no cardiac signal has been reported. No REMS has been mentioned in company disclosures.", "source": "EMBOLD poster, December 2025: https://praxismedicines.com/wp-content/uploads/2025/12/Gil-Nagel_AES2025_EMBOLD-Topline.pdf; Praxis corporate presentation, August 2026: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxiscorporatedeckaugus.htm; ClinicalTrials.gov NCT07010471: https://clinicaltrials.gov/study/NCT07010471" }, { "factor": "No approved therapy, and FDA has been approving rare neurological drugs on single small trials", "direction": "+", "step": "small", "evidence": "No drug is approved for SCN2A or SCN8A developmental and epileptic encephalopathy; relutrigine holds orphan drug and rare paediatric disease designations. In February 2026 FDA's commissioner and a senior deputy wrote that one pivotal trial plus confirmatory evidence is now the agency's default expectation. On 3 September 2026 FDA approved zilganersen, the first drug for Alexander disease, on one randomized trial of 49 patients. These describe the climate at FDA, not this review team's reading of this study.", "source": "Praxis 8-K exhibit 99.1, 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm; BioPharma Dive, 2026-02-19: https://www.biopharmadive.com/news/fda-makary-prasad0one-pivotal-trial-nejm/812557/; FDA press release, 2026-09-03: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease" }, { "factor": "Manufacturing cannot be checked from outside", "direction": "-", "step": "small", "evidence": "Praxis owns no manufacturing sites and relies on contract manufacturers for drug substance, drug product and packaging. None is named for relutrigine in its filings, so no inspection record (Form 483, warning letter or classification) can be looked up, and there is no public record of whether pre-approval inspections have taken place. It would be the company's first approved product. On the other side, the product is a small molecule in an oral liquid, simpler than a biologic or a sterile injectable; Praxis says FDA cited no manufacturing concerns when it extended the review, that the supply chain is established and that launch inventory is being built.", "source": "Praxis 10-K filed 2026-02-19 (Manufacturing; Risk Factors): https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm; Praxis 8-K, 2026-06-29: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm; Praxis 8-K exhibit 99.1, 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm; Q2 2026 results call transcript, 2026-08-06: https://www.fool.com/earnings/call-transcripts/2026/08/13/praxis-prax-q2-2026-earnings-call-transcript/" }, { "factor": "The company is preparing to launch and is not short of cash", "direction": "+", "step": "small", "evidence": "Praxis says the relutrigine commercial and medical teams are hired and trained, launch inventory is being built, and a patient support programme and payer discussions are under way. It reported $1.4 billion in cash and investments at 30 June 2026, enough by its estimate to fund operations into 2028, so its financing does not hinge on this approval. It made inducement grants to 66 new employees on 1 September and 14 on 1 October 2026. On 6 August it said it would give no further regulatory updates before the action dates, and it has filed no 8-K since (as of 5 October 2026), so the silence carries no information. Launch spending shows the company's confidence, not FDA's view: every favourable account of the review comes from the sponsor.", "source": "Praxis 8-K exhibit 99.1, 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm; Q2 2026 results call transcript, 2026-08-06: https://www.fool.com/earnings/call-transcripts/2026/08/13/praxis-prax-q2-2026-earnings-call-transcript/; Praxis press releases, 2026-09-03 and 2026-10-02: https://www.globenewswire.com/news-release/2026/09/03/3356230/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html and https://www.globenewswire.com/news-release/2026/10/02/3374007/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html; SEC EDGAR filing list for Praxis Precision Medicines (CIK 1689548)" } ], "manufacturing_risk": { "level": "medium", "why": "Relutrigine is a small molecule given as an oral liquid, by mouth or feeding tube, a simpler product than a biologic or a sterile injectable. Praxis owns no manufacturing sites and relies on contract manufacturers for drug substance, drug product and packaging. None is named for relutrigine in its filings, so their FDA inspection records cannot be checked, and there is no public record of whether pre-approval inspections have taken place. It would be the company's first approved product; the annual report filed in February 2026 said Praxis had not yet manufactured a commercial-scale product. In its favour, Praxis says FDA cited no manufacturing concerns when it extended the review in June 2026, and that the supply chain is established and launch inventory is being built. The company's summary of the mid-cycle meeting mentions safety and efficacy only. What cannot be judged: who the manufacturers are, their compliance status, and whether any manufacturing questions are open." }, "what_would_change_my_mind": [ "Down: Praxis discloses a manufacturing or facility-inspection problem, or says FDA has asked for further analyses or data.", "Down: the EMERALD study in broader epileptic encephalopathies, due to report in the fourth quarter of 2026, fails or shows a new safety signal before FDA acts.", "Down: FDA schedules an advisory committee meeting, or the goal date passes with no action and no explanation.", "Up: Praxis discloses that labeling discussions are complete, or that manufacturing-site inspections closed without findings.", "Up: EMERALD reports a positive result, with safety in line with EMBOLD, before FDA acts.", "Void rather than no: Praxis withdraws the application before FDA acts." ], "summary_en": "FDA approval of relutrigine in this review cycle is put at 80%, above the 76% base rate for first-time applications from smaller companies. In the registrational cohort of the EMBOLD study the drug cut seizures by 53% against placebo (p<0.0002), and the study stopped early for efficacy. Praxis reports priority review, a mid-cycle meeting with no major safety or efficacy concerns, no advisory committee and a clean sponsor inspection. Four things hold the estimate down: the evidence is one small study with an unusual control (a single 4-week placebo period in 25 of 53 children); FDA took three extra months to review added sensitivity analyses; few patients have been exposed; and the contract manufacturers are not named.", "summary_zh": "FDA 在本轮审评中批准 relutrigine 的概率估计为 80%，高于小公司首次申请 76% 的基准。在 EMBOLD 研究的注册队列中，该药相对安慰剂使癫痫发作减少 53%（p<0.0002），研究因疗效显著提前终止。Praxis 称该申请获优先审评，中期会议未发现重大安全性或有效性问题，FDA 不打算召开咨询委员会，对申办方的检查也没有发现问题。压低估计的因素有四：证据只有一项小型研究，对照方式少见（53 名患儿中 25 名各有一段 4 周安慰剂期）；FDA 为审阅补充的敏感性分析多用了三个月；用药人数少；合同生产商未公开。", "sources": [ "Praxis 8-K, 2026-06-29 (review extended; goal date 27 December 2026): https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm", "Praxis 8-K exhibit 99.1, 2026-08-06 (Q2 2026 results and corporate update): https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm", "Praxis 10-Q for Q2 2026, filed 2026-08-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm", "Praxis corporate presentation, August 2026 (8-K exhibit 99.2): https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxiscorporatedeckaugus.htm", "Praxis Q2 2026 results call transcript, 2026-08-06: https://www.fool.com/earnings/call-transcripts/2026/08/13/praxis-prax-q2-2026-earnings-call-transcript/", "Praxis press release, 2026-03-30 (NDA accepted for priority review): https://www.globenewswire.com/news-release/2026/03/30/3264996/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Relutrigine-in-Patients-with-SCN2A-and-SCN8A-DEEs.html", "Praxis 8-K, 2026-04-06: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/prax-20260406.htm", "Praxis 10-K for FY2025, filed 2026-02-19: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm", "Praxis 8-K exhibit 99.1, 2026-02-19 (NDA submitted): https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm", "Praxis 8-K, 2025-12-11 (FDA discussion; plan to file): https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/prax-20251209.htm", "Praxis 8-K, 2025-12-08 (EMBOLD registrational cohort results): https://www.sec.gov/Archives/edgar/data/1689548/000168954825000114/prax-20251204.htm", "Praxis press release, 2025-11-04 (FDA alignment on EMBOLD and the interim analysis): https://www.globenewswire.com/news-release/2025/11/04/3180282/0/en/praxis-announces-accelerated-development-path-for-relutrigine-in-scn2a-and-scn8a-dee-patients-following-positive-fda-feedback.html", "Praxis 8-K exhibit 99.1, 2025-11-05: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm", "Praxis 8-K, 2025-07-17 (Breakthrough Therapy Designation): https://www.sec.gov/Archives/edgar/data/1689548/000168954825000086/prax-20250717.htm", "EMBOLD poster, American Epilepsy Society meeting, December 2025 (Kamireddy et al.): https://praxismedicines.com/wp-content/uploads/2025/12/Gil-Nagel_AES2025_EMBOLD-Topline.pdf", "American Epilepsy Society abstract 1.38, December 2025 (EMBOLD open-label extension): https://aesnet.org/abstractslisting/relutrigine-demonstrates-sustained-seizure-reduction-with-continued-exposure-on-top-of-standard-of-care-results-from-the-embold-open-label-extension", "ClinicalTrials.gov NCT05818553 (EMBOLD): https://clinicaltrials.gov/study/NCT05818553", "ClinicalTrials.gov NCT07010471 (EMERALD): https://clinicaltrials.gov/study/NCT07010471", "PRAX-562-101 phase 1 poster, 2023: https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf", "PRAX-562-102 phase 1 poster, 2023: https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-102_Final_QRcode.pdf", "Fierce Biotech, 2026-06-30: https://www.fiercebiotech.com/biotech/praxis-faces-fda-delay-analysts-point-finger-agency-layoffs", "BioSpace, 2026-06-30: https://www.biospace.com/fda/fda-hits-praxis-with-3-month-delay-for-epilepsy-drug-verdict", "PDUFA Reauthorization Performance Goals and Procedures FY2023-2027: https://www.fda.gov/media/151712/download", "Rhythm Pharmaceuticals press release, 2026-03-19 (8-K exhibit): https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm", "FDA advisory committee calendar, viewed 2026-10-05: https://www.fda.gov/advisory-committees/advisory-committee-calendar", "FDA press release, 2026-09-03 (zilganersen for Alexander disease): https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease", "BioPharma Dive, 2026-02-19 (one pivotal trial as FDA's default): https://www.biopharmadive.com/news/fda-makary-prasad0one-pivotal-trial-nejm/812557/", "Praxis press release, 2026-09-03 (inducement grants): https://www.globenewswire.com/news-release/2026/09/03/3356230/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "Praxis press release, 2026-10-02 (inducement grants): https://www.globenewswire.com/news-release/2026/10/02/3374007/0/en/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "SEC EDGAR filing list for Praxis Precision Medicines (CIK 1689548), as of 2026-10-05", "openFDA Drugs@FDA and complete response letter databases, queried 2026-10-05: no record for relutrigine", "PubMed search for relutrigine / PRAX-562, 2026-10-05; Martins, Curr Issues Mol Biol 2026: https://doi.org/10.3390/cimb48080830; Bialer et al., Epilepsia 2026: https://doi.org/10.1002/epi.70346" ], "zh": { "indication": "SCN2A 和 SCN8A 发育性癫痫性脑病（DEE）", "key_factors": [ { "factor": "注册队列以明显优势达到主要终点", "evidence": "在 EMBOLD 研究的注册队列（队列 2）中，relutrigine 在 16 周内使每月运动性癫痫发作相对安慰剂减少 53%（p<0.0002）。促成研究提前终止的期中分析按 4% 的显著性水平检验，这一结果远远越过了门槛。关键次要终点同样显著：无运动性发作天数增加 66.2%（p=0.0340），临床医生和照护者的总体印象评分均偏向 relutrigine（-2.62，p<0.0001；-3.7，p=0.002）。第一个队列采用相同设计、起始剂量较低，经安慰剂校正的降幅为 46%（p=0.0354；使用 relutrigine 的患者 15 名，安慰剂期 7 个）。超过 80% 的患者入组时已在使用钠通道阻滞剂。Praxis 称疗效在 SCN2A 和 SCN8A 患者中一致，但亚组数据未公开。" }, { "factor": "FDA 事先同意这一项研究可以支撑申请", "evidence": "Praxis 于 2025 年 11 月 4 日披露，在一次 Type B 会议以及就方案和统计分析计划获得书面意见之后，已与 FDA 达成一致：正在进行的 EMBOLD 研究可作为有效性实质性证据的基础；FDA 还同意，期中分析若为阳性，可作为提交 NDA 的依据。FDA 已于 2025 年 7 月依据第一个队列及其 11 个月的开放标签随访授予突破性疗法认定。期中结果出来后，公司在 2025 年 12 月与 FDA 再次沟通，随后确认提交申请。以上均为公司的说法，FDA 的会议纪要未公开。" }, { "factor": "目前披露的审评信号偏正面", "evidence": "FDA 受理该申请并给予优先审评（2026 年 3 月 30 日公布）。2026 年 8 月 6 日，Praxis 表示中期会议已经完成，FDA 迄今未发现重大的安全性或有效性问题，并确认不打算召开咨询委员会会议；FDA 的咨询委员会日程上也没有与该药有关的会议。FDA 依据生物研究监查（Bioresearch Monitoring）项目对申办方进行了检查，范围包括数据完整性以及统计分析和期中分析，结束时未开出 Form 483。有两点局限：这些都是申办方的转述；关于中期会议的表述没有提到生产。" }, { "factor": "研究规模小，对照方式少见", "evidence": "注册队列只随机入组了 53 名患儿，原计划为 80 名，因为研究在期中分析时即告终止。研究没有平行的安慰剂组：所有患者都被分配使用 relutrigine，其中 25 名在 16 周内还被安排了一段为期 4 周的设盲安慰剂期。因此，所谓经安慰剂校正的结果，是把 51 名患者使用 relutrigine 的时段，与 25 名患者各自仅有的一段 4 周安慰剂期相比，而这 25 名患者大多也在那 51 名之中。事先商定的主要分析是对经对数转换的发作次数做 ANCOVA，公开说明的因素只有治疗分组。未公开的是：安慰剂期落在 16 周中的哪一段，以及如何处理此前用药的残留效应或停药后的反跳。PubMed 未收录该结果的同行评议论文；公开资料只有一张会议壁报和公司新闻稿。" }, { "factor": "FDA 多用了三个月审阅补充的疗效数据分析", "evidence": "2026 年 6 月 29 日，FDA 把 PDUFA 目标日期从 2026 年 9 月 27 日推到 2026 年 12 月 27 日，起因是 Praxis 提交了对现有临床数据的补充敏感性分析，FDA 将其认定为重大补充。Praxis 称 FDA 没有要求新的研究，也没有提出安全性或生产方面的问题。据 Fierce Biotech 转述 TD Cowen 的说法，公司称这次提交内容简单，仅限于小幅的敏感性分析以及数据格式和呈现方式的调整；这些分析究竟检验了什么并未公开。延期通常不是坏消息：FDA 的使用者付费承诺把对已提交研究的重大再分析列为典型的重大补充，并写明除极少数情况外，延期应限于新资料有可能促成本轮获批的情形。BioSpace 援引 Jefferies 的统计称，延期审评中超过 80% 最终获批；Rhythm 的 setmelanotide 补充申请因同样的理由被延期后，于 2026 年 3 月获批。但这也说明，对于申请所依赖的唯一一项研究，FDA 需要的比最初提交的更多。每个审评周期只能延期一次；2026 年 12 月 27 日是星期日。" }, { "factor": "用药人数少", "evidence": "设盲期的安全性数据覆盖 67 名患儿：第一个队列 16 名，注册队列 51 名，每人用药最长 16 周。目前公布的长期结果只涉及 13 名随访 11 个月的患者。两项健康成人 1 期研究分别入组 112 人和 48 人。规模更大的安慰剂对照研究 EMERALD 纳入约 200 名各种病因的癫痫性脑病患者，目前仍处于设盲状态，FDA 已收到其中多少安全性数据并未公开。注册队列中有 1 例死亡和 1 例撤回知情同意被列为安慰剂期间的退出。从壁报的人数看（随机入组 53 名，relutrigine 安全性分析 51 名），这两名患者应是在使用 relutrigine 之前退出的；死因未公开，Praxis 称没有与药物相关的严重不良事件。对于一种拟在儿童中长期使用的新化学实体，这样的数据基础偏薄，不过据 Praxis 称，FDA 在中期会议上没有提出重大安全性问题。" }, { "factor": "已披露的耐受性数据干净", "evidence": "在注册队列中，最常见不良事件按暴露量校正后的发生率，relutrigine 与安慰剂相近或更低（每 100 患者月：发热 11.74 对 13.35；嗜睡 9.13 对 13.35；腹泻 4.57 对 8.90），上呼吸道感染则是 relutrigine 更高（9.79 对 4.45）。Praxis 称没有与药物相关的严重不良事件，无人需要减量，生命体征、实验室检查和心电图均无有临床意义的异常；有 1 名患者在使用 relutrigine 期间因不良事件退出。正在进行的 EMERALD 研究排除了家族性短 QT 综合征、Brugada 综合征和某些心律失常患者，说明心脏传导是受到监测的风险；目前没有心脏方面信号的报告。公司披露中未提到 REMS。" }, { "factor": "尚无获批疗法，且 FDA 近来凭单项小型试验批准罕见神经疾病药物", "evidence": "SCN2A 或 SCN8A 发育性癫痫性脑病目前没有获批药物；relutrigine 拥有孤儿药和罕见儿科疾病资格。2026 年 2 月，FDA 局长和一位高级副手撰文称，一项关键试验加上佐证证据已成为该机构的默认要求。2026 年 9 月 3 日，FDA 凭一项纳入 49 名患者的随机试验批准了 zilganersen，这是首个治疗 Alexander 病的药物。这些说明的是 FDA 当前的大环境，而不是本申请审评团队对这项研究的看法。" }, { "factor": "生产环节无法从外部核实", "evidence": "Praxis 没有自己的生产设施，原料药、制剂和包装都依靠合同生产商。公司披露文件没有点名 relutrigine 的任何生产商，因此查不到相关的检查记录（Form 483、警告信或检查定性），公开资料也未见批准前检查是否已经进行。这将是该公司第一个获批的产品。另一方面，该产品是口服液体剂型的小分子药，比生物制品或无菌注射剂简单；Praxis 称 FDA 在延长审评时没有提出生产方面的问题，供应链已经建立，上市库存正在备货。" }, { "factor": "公司在为上市做准备，资金充裕", "evidence": "Praxis 称 relutrigine 的商业和医学团队已招聘并培训到位，上市库存正在备货，患者支持项目和与支付方的沟通也在推进。公司披露截至 2026 年 6 月 30 日持有 14 亿美元（$1.4 billion）现金和投资，按其估计可支撑运营到 2028 年，融资并不取决于此次获批。公司于 2026 年 9 月 1 日向 66 名新员工、10 月 1 日向 14 名新员工授予了入职股权激励。8 月 6 日公司表示，在目标日期之前不再通报监管进展，此后也没有再提交 8-K（截至 2026 年 10 月 5 日），所以这段沉默不含任何信息。上市投入反映的是公司的信心，而不是 FDA 的看法：有关审评的正面说法全部出自申办方。" } ], "manufacturing_risk_why": "Relutrigine 是口服液体剂型的小分子药，可经口或经喂养管给药，比生物制品或无菌注射剂简单。Praxis 没有自己的生产设施，原料药、制剂和包装都依靠合同生产商。公司披露文件没有点名 relutrigine 的任何生产商，因此无法查证这些场地的 FDA 检查记录，公开资料也未见批准前检查是否已经进行。这将是该公司第一个获批的产品；2026 年 2 月提交的年报写明，Praxis 当时尚未生产过商业规模的产品。有利的一面是：Praxis 称 FDA 在 2026 年 6 月延长审评时没有提出生产方面的问题，供应链已经建立，上市库存正在备货。公司对中期会议的概述只提到安全性和有效性。无法判断的部分：生产商是谁、其合规状况如何，以及是否还有未解决的生产问题。", "what_would_change_my_mind": [ "下调：Praxis 披露生产或场地检查方面出现问题，或表示 FDA 要求补充分析或数据。", "下调：针对更广泛癫痫性脑病的 EMERALD 研究预计在 2026 年第四季度公布结果，若在 FDA 作出决定前宣告失败或出现新的安全性信号。", "下调：FDA 安排召开咨询委员会会议，或目标日期已过而 FDA 既未作出决定也没有说明。", "上调：Praxis 披露标签讨论已经完成，或生产场地检查已结束且没有发现问题。", "上调：EMERALD 在 FDA 作出决定前公布阳性结果，且安全性与 EMBOLD 一致。", "作废而非判否：Praxis 在 FDA 作出决定前撤回申请。" ] }, "recorded_at": "2026-10-05T08:21:33+00:00" }